TY  - GEN
AU  - Sugimoto,T
AU  - Matsumoto,T
AU  - Hosoi,T
AU  - Miki,T
AU  - Gorai,I
AU  - Yoshikawa,H
AU  - Tanaka,Y
AU  - Tanaka,S
AU  - Fukunaga,M
AU  - Sone,T
AU  - Nakano,T
AU  - Ito,M
AU  - Matsui,S
AU  - Yoneda,T
AU  - Takami,H
AU  - Watanabe,K
AU  - Osakabe,T
AU  - Okubo,N
AU  - Shiraki,M
AU  - Nakamura,T
TI  - Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)
SN  - 1433-2965
PY  - 2015///1214
KW  - Aged
KW  - Biomarkers
KW  - blood
KW  - Bone Density
KW  - drug effects
KW  - Bone Density Conservation Agents
KW  - administration & dosage
KW  - Bone Remodeling
KW  - Calcium
KW  - therapeutic use
KW  - Denosumab
KW  - Double-Blind Method
KW  - Drug Administration Schedule
KW  - Drug Therapy, Combination
KW  - Female
KW  - Humans
KW  - Injections, Subcutaneous
KW  - Male
KW  - Middle Aged
KW  - Osteoporosis
KW  - complications
KW  - Osteoporosis, Postmenopausal
KW  - Osteoporotic Fractures
KW  - etiology
KW  - Spinal Fractures
KW  - Vitamin D
N1  - Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1007/s00198-014-2964-2
ER  -